Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382668 · ClinicalTrials.gov registry record
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
A clinical trial of Liver Diseases, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 40
- Enrollment target
- 4
- Study locations
NCT00382668 is a study of Liver Diseases that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants, below the 61,157-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00382668, a study of Liver Diseases, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (4)
Florida
- University Of Miami - Miami
- Comprehensive Phase One - Miramar
- Orlando Clinical Research Center - Orlando
Tennessee
- New Orleans Center For Clinical Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382668
The ClinicalTrials.gov registry entry for NCT00382668 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,157-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT00382668 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00382668 about?
NCT00382668 is a clinical study titled "A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug". The primary purpose of this study is to evaluate how a person with liver impairment processes and reacts to the study drug. Information about any side effects that may occur will also be collected.
What is the current status of trial NCT00382668?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2007-08.
What conditions does trial NCT00382668 study?
This clinical trial studies the following conditions: Liver Diseases.
What interventions are being tested in trial NCT00382668?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00382668?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00382668 being conducted?
This trial has 4 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Genetic Collection Protocol
RECRUITING
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.